基于基线和HALP动态变化的高级NSCLC免疫治疗的预后价值
Hui Su1, Chao Yu2, Guiming Sun3
1Department of Oncology, Medical College of Qingdao University, Qingdao, China; Department of Oncology, Liaocheng People's Hospital, Liaocheng, China.
Biomolecules & biomedicine
|July 22, 2024
概括
血红蛋白,白蛋白和血小板 (HALP) 水平,以及中性粒细胞与淋巴细胞的比率 (NLR) 和血小板与淋巴细胞的比率 (PLR),可以预测晚期非小细胞肺癌 (NSCLC) 的免疫治疗反应. 低HALP和高NLR/PLR表明接受免疫治疗的NSCLC患者的预后不佳.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
背景情况:
- 免疫检查点抑制剂 (ICI) 已经彻底改变了高级非小细胞肺癌 (NSCLC) 治疗,改善了生存率.
- 然而,由于反应率低,缺乏可靠的生物标志物,预测ICI疗效和患者选择仍然存在挑战.
研究的目的:
- 评估血红蛋白,白蛋白和血小板 (HALP),中性粒细胞与淋巴细胞比率 (NLR) 和血小板与淋巴细胞比率 (PLR) 对晚期NSCLC免疫疗法的疗效和生存的影响.
- 根据这些血液学参数,开发一个预测性血谱.
主要方法:
- 从203名先进NSCLC患者的临床和血液学数据分析,这些患者接受了免疫治疗.
- 使用固体瘤免疫反应评估标准 (iRECIST),无进展生存率 (PFS) 和整体生存率 (OS) 评估疗效.
- 将基线和治疗后的HALP,NLR和PLR值纳入预测模型.
主要成果:
- 治疗前的血小板与淋巴细胞比率 (PLR0) 与更高的疾病控制率 (DCR) 相关联.
- 治疗前的HALP (HALP0),治疗后的HALP (HALP4C) 和治疗前的NLR (NLR0) 显著影响了PFS.
- HALP0,NLR0和治疗后PLR (PLR4C) 与OS相关,PFS的C指数为0.823,OS的C指数为0.878.
结论:
- 在不同时间点的HALP,NLR和PLR是高级NSCLC免疫疗法反应的有效预测剂.
- 低HALP与高NLR和PLR相结合,表明接受免疫治疗的NSCLC患者的预后不佳.
- 这些发现支持对NSCLC免疫治疗进行分层随机对照试验的发展.
相关概念视频
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...